DETERMINATION: the addition of ASCT to lenalidomide, bortezomib, and dexamethasone provides a PFS advantage for patients with newly diagnosed multiple myeloma
For decades, autologous stem cell transplants (ASCTs) with high-dose chemotherapy has been the standard of care for patients with newly…
Approval of axi-cel in second-line for R/R LBCL & label update
Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…
Real-world data in multiple myeloma: treating patients beyond 1L
Case study discussions with Prof. Graham Jackson & Irish clinicians. Commissioned & fully funded by Takeda Products Ireland Ltd.
Amyloidosis: current challenges and future outlooks
VJHemOnc is excited to bring you a feature covering current challenges and future outlooks in amyloidosis.
Ciltacabtagene autoleucel receives FDA approval for R/R multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…
Highlights from the EBMT-EHA CAR T-cell 2022 Meeting
VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell…
VJSocial Media Masterclass
Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals